Glucagon enhanced insulin absorption in Diabetes Mellitus type 1
Key facts
- Where
- Trondheim, NorvégiaSee the site
- Phase
- 2. fázis
Where in Norvégia
- St. Olavs hospital HFTrondheim, NorvégiaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- St. Olavs Hospital HF
- Trial code
- EU 2022-502455-57-01
- Record updated
- 2023. március 29.
- Original description
To investigate if micro-doses of glucagon at the same site as subcutaneous insulin delivery enhances the absorption of insulin and reduces postprandial glucose excursions in patients with diabetes mellitus type 1Read full original descriptionShow less
To investigate if micro-doses of glucagon at the same site as subcutaneous insulin delivery enhances the absorption of insulin and reduces postprandial glucose excursions in patients with diabetes mellitus type 1
Inclusion: DM1 for at least 1 year; Age 18 – 70 years; Last known HbA1c <86 mmol/mol (< 10.0%); Treated with continuous SC insulin infusion (CSII) by an insulin pump or with multiple daily insulin injections (MDII).
Exclusion: Any chronic disease, including psychiatric illnesses, judged incompatible with participation in the study; Known hypersensitivity to glucagon or any of the excipients of the drug formulation; Pregnant women or women trying to conceive (women will not be screened by a pregnancy test); Unfit for participation for any reason as judged by the investigators; Known phaeochromocytoma.